Peptide Field Book

Reading settings

Choose a comfortable text size and appearance. Your choices are saved on this device.

Community field notes

Community protocols.

Collected reports, with their sources.

238 protocols675 source citationsJump to the 12 stacks

These entries describe reported practices; inclusion does not verify a product’s identity or quality. Each row shows a reported protocol and links to its sources. Frequency labels mean frequently encountered in reviewed sources; the sampling frame is unknown.

Stacks

46 peptides and blendsCollection date: 30 Sep 2026

Weight & metabolism.

Growth hormone.

Healing & repair.

Immune system.

Skin, hair & tanning.

Brain, mood & sleep.

Longevity.

Sexual health.

Blends.

Stacks. Several peptides, taken together.

12 stacks · Reported online

Wolverine stack (BPC-157 + TB4/TB-500, separate vials)

Made ofBPC-157Thymosin Beta-4

The standard version is BPC-157 250–500 mcg a day plus TB4 (sold as TB-500) 2–2.5 mg twice a week for 4–6 weeks, then 2–2.5 mg once a week.

More about this

Some users take small daily TB4 doses instead. A nasal-spray version is also sold.

Not testedFrequently encountered in reviewed sources

Loading, then maintenance

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
BPC-157: 250–500 mcg a day (often 250 mcg twice a day). TB4: 2–2.5 mg twice a week (4–5 mg a week) while loading, then 2–2.5 mg once a week.
How often
BPC-157 once or twice a day. TB4 twice a week, then once a week.
Route
Injection under the skin; BPC-157 is often injected near the injury
How long
Loading 4–6 weeks, then maintenance for about 4–8 more weeks
Cycle
One clinic cycles BPC-157 4–8 weeks on, 4 weeks off
Ramp
Front-loaded TB4 (loading phase), then a lower maintenance rate
Mixing
Separate vials. Example from a vendor guide: 5 mg BPC-157 + 2.5 mL water (250 mcg = 12.5 units); 5 mg TB4 + 2 mL water (2.5 mg = 100 units).
  • Calculated (vendor example): 5 mg in 2.5 mL = 2 mg/mL, so 250 mcg is 0.125 mL (12.5 units). 5 mg in 2 mL = 2.5 mg/mL, so 2.5 mg is 1 mL (a full 100-unit syringe).
  • A 1:1 pre-mixed vial cannot match this pattern, because TB4 is dosed in milligrams a few times a week and BPC-157 in micrograms daily.
Sources (4)

Not testedCommon

Forum variants on the TB4 schedule

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
BPC-157 250–500 mcg once or twice a day, with TB4 anywhere from 1 mg twice a week to 5 mg every 5 days, or small TB4 doses every day
How often
BPC-157 daily; TB4 every few days, weekly, or daily
Route
Injection under the skin (belly)
How long
About 8 weeks
Cycle
Then 1–2 months off (one user’s advice)
  • Users disagree on whether BPC-157 needs cycling; one cites a practitioner saying it does not, while TB4 should be cycled.
Sources (4)
Show all 3 protocolsShow fewer protocols

Not testedSometimes seen

Nasal spray (pre-mixed BPC-157 + TB-500)

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
50 mcg per spray (standard) or 100 mcg per spray (‘Ultra’), as sold. Sprays per day are not stated on the product page.
How often
Daily
Route
Nasal spray
How long
One reviewer used it for about 4 weeks, then planned a week off
Mixing
Sold ready-made: 10 mg in 10 mL (100 sprays)
  • Calculated 10 mg in 10 mL = 1 mg/mL, so a 50 mcg spray is about 0.05 mL. The label does not say how the 50 mcg splits between BPC-157 and TB-500.
Sources (2)

Where the numbers come from

The name refers to the Marvel character’s fast healing. The pairing spread through bodybuilding and biohacking forums and vendor marketing, and later through regenerative clinics. The doses are forum and clinic conventions (BPC-157 in micrograms daily, TB4 in milligrams with a loading phase), not results from any human trial of the pair.

Cautions

Research notes

Vendors sell ‘TB-500’ as either full thymosin beta-4 or the short 17–23 fragment, and labels do not always say which; the FDA’s concerns name the fragment. In July 2026 an FDA advisory panel voted to recommend letting pharmacies compound BPC-157 and TB-500; the FDA had not decided at the time of writing.

CJC-1295 (no DAC) + ipamorelin (separate vials)

Made ofCJC-1295 (no DAC)Ipamorelin

Same doses as the pre-mixed blend, drawn from two vials into one syringe: usually 100 mcg of each at bedtime, 5 nights a week. Forum users also take 100 mcg of each 2–3 times a day.

Not testedFrequently encountered in reviewed sources

Bedtime, 5 nights a week

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
100 mcg of each (some clinics go to 200–300 mcg of each)
How often
Once a day, 5 days on and 2 days off
Route
Injection under the skin; both drawn into the same syringe
Timing
Before bed, on an empty stomach
How long
About 3 months
Cycle
One clinic: 3 months on, 1 month off
Mixing
Separate vials, each mixed with bacteriostatic water
Sources (2)

Not testedCommon

Three times a day (‘saturation dose’)

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
100 mcg of each per shot
How often
3 times a day (morning, after training, bedtime)
Route
Injection under the skin
Timing
Empty stomach; wait about 30 minutes before eating
Mixing
5 mg vial of each + 3 mL bacteriostatic water; 6 units of each = 100 mcg
  • Calculated 5 mg in 3 mL = 1.67 mg/mL, so 6 units (0.06 mL) = 100 mcg of each.
Sources (3)

Where the numbers come from

Bodybuilding-forum guides on pairing growth-hormone-releasing drugs (by ‘Datbtrue’, around 2010) set the 100 mcg ‘saturation dose’ and the pre-bed shot. Clinics later settled on once nightly, 5 nights a week.

Cautions

Research notes

The ExcelMale user wrote ‘100mg’ where he meant 100 mcg; his arithmetic only works for mcg. Same cautions as the pre-mixed blend (b-cjcipa).

Day CJC-1295/ipamorelin + night tesamorelin/ipamorelin

Made ofCJC-1295 (no DAC)IpamorelinTesamorelin

Some users combine the two growth-hormone-releasing pairs: CJC-1295 with ipamorelin in the morning and before training, and tesamorelin with ipamorelin at night. Only single-user reports were found.

Not testedFringe

CJC/ipamorelin by day, tesamorelin/ipamorelin at night

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Morning and pre-workout: 100 mcg CJC-1295 no DAC + ipamorelin. Night: 2 mg tesamorelin + 100 mcg ipamorelin.
How often
3 shots a day
Route
Injection under the skin
Timing
Fasted for each shot
Sources (2)

Where the numbers come from

User-built, extending the CJC/ipamorelin and tesamorelin/ipamorelin pairs.

Research notes

Single-user report; the same user also took GHK-Cu, low-dose tirzepatide and other peptides at the same time. Vendors also sell a 3-in-1 tesamorelin/CJC-1295/ipamorelin vial (commonly 6/3/3 mg) that is not sold here; its dosing was not researched for this entry.

Retatrutide + cagrilintide

Made ofRetatrutideCagrilintide

Users add a low weekly dose of cagrilintide (commonly 0.25–0.5 mg, some up to 1–2 mg) to weekly retatrutide (about 2–10 mg) when appetite control fades. Many warn to start low: users who began at 2.5 mg of cagrilintide describe days of exhaustion and being unable to eat.

Not testedCommon

Low-dose cagrilintide added to weekly retatrutide

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Cagrilintide 0.25–0.5 mg a week (some start at 0.1 mg; a few use 1–2 mg). Retatrutide at the user’s usual dose, about 2–10 mg a week.
How often
Once a week for each (some take cagrilintide every 4–5 days as needed)
Route
Injection under the skin (separate shots, or one pre-mixed vial from some sellers)
Ramp
Start at 0.25 mg (or 0.1 mg) of cagrilintide and raise slowly. Some advise maxing out retatrutide before adding it.
  • Stated reason: to bring back appetite suppression when retatrutide alone stops working.
Sources (4)

Not testedFringe

Three-drug stack (retatrutide + tirzepatide + cagrilintide)

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Retatrutide 7.5 mg + tirzepatide 10 mg + cagrilintide 2 mg a week, on different days
How often
Each once a week
Route
Injection under the skin
  • Other users called this far too much. One wrote that most people lose weight on 2–4 mg of retatrutide a week.
Sources (1)

Where the numbers come from

Copies the idea of Novo Nordisk’s CagriSema (cagrilintide plus semaglutide) with retatrutide swapped in. The cagrilintide doses (0.25 mg rising toward 2.4 mg) echo the CagriSema trial ladder. No study has tested retatrutide with cagrilintide.

Cautions

Show all 4 cautionsShow fewer cautions
Research notes

Both drugs are investigational and are bought as research vials. Some sellers now offer retatrutide and cagrilintide in one vial; a user asked whether they are chemically compatible, and no testing was found. One thread cites a paper on amylin analogues forming clumps (fibrils).

MOTS-c + SS-31 (mitochondrial stack)

Made ofMOTS-cSS-31

Users usually run SS-31 daily for 3–4 weeks at 4–5 mg (some 10 mg), and add or follow with MOTS-c at 5–10 mg about 3 times a week.

More about this

Some cut MOTS-c to once a week, then take a month off. Doses vary widely, from 0.5 mg to 20 mg of SS-31 a day.

Not testedFrequently encountered in reviewed sources

SS-31 block, then MOTS-c

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
SS-31 4–5 mg a day for 20–30 days (some raise it to 10 mg). MOTS-c 5–10 mg about 3 times a week, alongside or afterwards.
How often
SS-31 once a day (some 5 days on, 2 off). MOTS-c 3 times a week, later once a week.
Route
Injection under the skin
How long
About 2–3 months in total
Cycle
One user: month 4 off
Ramp
SS-31 first, MOTS-c layered in during month 2
Sources (3)

Not testedSometimes seen

Low-dose SS-31

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
SS-31 500 mcg a day
How often
Once a day
Route
Injection under the skin
How long
2 weeks reported
Sources (1)
Show all 3 protocolsShow fewer protocols

Not testedFringe

High dose

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
MOTS-c 10 mg per injection on weekdays; SS-31 20 mg once a day
How often
MOTS-c Monday to Friday; SS-31 daily
Route
Injection under the skin
Cycle
Then 3 months off (as described)
  • Other users replied that 20 mg of SS-31 is higher than almost every protocol.
Sources (1)

Where the numbers come from

User-built ‘mitochondrial’ pairing. SS-31 doses of several mg a day loosely echo drug-trial doses of elamipretide (the approved form is a daily injection for Barth syndrome). MOTS-c doses come from vendor and forum convention; the FDA says it has found no human exposure data for MOTS-c.

Cautions

Research notes

Dose ranges are very wide and unanchored. In July 2026 an FDA advisory panel voted 7–5 to recommend allowing pharmacies to compound MOTS-c; the FDA had not decided at the time of writing.

‘Deadpool’ healing stack (BPC-157 + TB4 + ipamorelin + tesamorelin + GHK-Cu, separate vials)

Made ofBPC-157Thymosin Beta-4IpamorelinTesamorelinGHK-Cu

A 2025 Reddit post branded a five-peptide separate-vial stack as the ‘Deadpool’ protocol: BPC-157 and TB4 for repair, ipamorelin and tesamorelin for growth hormone, and GHK-Cu, for 30–45 days.

More about this

It is not the same as the vendor’s ‘Deadpool Blend’ vial.

Not testedFringe

Five-peptide 30–45 day course

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
BPC-157 250–350 mcg twice a day or 500–700 mcg once a day; TB4 2.5–5 mg 2–3 times a week or 1 mg daily; ipamorelin 100–300 mcg 1–3 times a day; tesamorelin 1 mg 1–2 times a day; GHK-Cu 5 mg a day
How often
Daily; ipamorelin and tesamorelin 5 days a week
Route
Injection under the skin (BPC-157 and TB4 sometimes into a muscle)
Timing
Tesamorelin before bed (at least 90 minutes after eating) or on waking before exercise
How long
30–45 days (tesamorelin 6–8 weeks)
Sources (3)

Where the numbers come from

Posted by one Reddit account in April 2025; a commenter asked the poster to disclose ties to peptide companies. The poster later added that CJC-1295 no DAC can be included.

Research notes

The name ‘Deadpool’ is used for at least four different products (see b-deadpool). The 5 mg daily GHK-Cu here is more than twice the 1.5–2 mg most GLOW/KLOW users aim for.

Tirzepatide + cagrilintide

Made ofTirzepatideCagrilintide

Users add cagrilintide at 0.25–0.5 mg a week (a few up to 2 mg) to their tirzepatide to push past a weight-loss stall or quiet ‘food noise’. Some take it only when hunger comes back.

More about this

One user reported a hospital stay after adding it.

Not testedCommon

Low-dose cagrilintide added to tirzepatide

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Cagrilintide 0.25–0.5 mg a week (some start at 0.3 mg; a few use 2 mg), on top of the user’s usual tirzepatide dose
How often
Once a week, often 3–4 days after the tirzepatide shot; some only ‘as needed’
Route
Injection under the skin (separate shot)
Ramp
Start at 0.25–0.3 mg for about 3 weeks, then 0.5 mg. Some copy the CagriSema trial ladder.
  • Stated reasons: a weight-loss stall, or side effects that stop the user raising tirzepatide further.
Sources (4)

Not testedSometimes seen

Shorter interval: lower tirzepatide with cagrilintide every 5 days

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Tirzepatide 10 mg + cagrilintide 0.25 mg
How often
Every 5 days
Route
Injection under the skin
  • The user moved from 15 mg every 8 days to this after getting hungry by day 6.
Sources (1)

Where the numbers come from

A do-it-yourself version of Novo Nordisk’s CagriSema idea (cagrilintide plus a GLP-1 drug), with tirzepatide in place of semaglutide. No study has tested tirzepatide with cagrilintide.

Cautions

Research notes

Tirzepatide is approved (Mounjaro, Zepbound); cagrilintide is investigational and bought as a research vial. Some sellers offer pre-mixed tirzepatide/cagrilintide vials (for example 5 mg/5 mg); no testing of those mixes was found.

Semaglutide + cagrilintide (do-it-yourself ‘CagriSema’)

Made ofSemaglutideCagrilintide

A few users add a small dose of research cagrilintide (about 0.25 mg a week) to semaglutide to break a stall, copying Novo Nordisk’s CagriSema combination. Fewer reports were found than for tirzepatide or retatrutide with cagrilintide.

Not testedSometimes seen

Small cagrilintide dose added to semaglutide

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Cagrilintide 0.25 mg (250 mcg) a week added to the user’s semaglutide (one user: 1 mg a week)
How often
Once a week each
Route
Injection under the skin (separate shots)
  • The user said the pairing ‘killed’ appetite, and chose it because Novo Nordisk was testing the same two drugs together.
  • Novo’s own CagriSema trial doses are covered in the verified section; research-vial users often borrow its 0.25 mg starting step.
Sources (3)

Where the numbers come from

Copies Novo Nordisk’s CagriSema (cagrilintide + semaglutide), made from separate research or compounded vials.

Cautions

Research notes

Thin evidence: only a few forum reports found. One user’s stack also included mazdutide, which is not on this site.

Tirzepatide + retatrutide

Made ofTirzepatideRetatrutide

Users stack weekly tirzepatide and retatrutide when weight loss stalls, when retatrutide alone leaves them hungry, or while switching from one to the other. Reported weekly pairs include 5 + 5 mg, 2.5 + 2.5 mg, 7.5 mg tirzepatide + 10 mg retatrutide, and 10 mg tirzepatide + 4 mg retatrutide.

More about this

Some take small daily doses of both. Others argue the combination is pointless.

Not testedCommon

Two weekly shots

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Tirzepatide 2.5–10 mg + retatrutide 2.5–10 mg a week (for example 5 mg + 5 mg, or 2.5 mg + 2.5 mg)
How often
Each once a week, often on different days
Route
Injection under the skin
  • Stated reasons: a stall on either drug, hunger or sweet cravings on retatrutide alone, or keeping what users feel is tirzepatide’s anti-inflammatory effect.
  • A commenter who says they are a biologist argued that retatrutide already covers tirzepatide’s receptors more strongly, so adding tirzepatide is wasted money. Others disagreed.
Sources (4)

Not testedCommon

Switching over: lower one while raising the other

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Retatrutide 1–2 mg added to tirzepatide 5–15 mg; tirzepatide stepped down every 2 weeks (15, 12.5, 10, 7.5, 5 mg) while retatrutide rises every 4 weeks (2, 4, 6 mg)
How often
Weekly (some split into two shots)
Route
Injection under the skin
Ramp
Retatrutide up every 4 weeks; tirzepatide down every 2 weeks (one user’s schedule)
Sources (4)
Show all 4 protocolsShow fewer protocols

Not testedSometimes seen

Small daily doses of both

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Tirzepatide 0.7 mg + retatrutide 0.3 mg a day (4.9 mg + 2.1 mg a week)
How often
Every day
Route
Injection under the skin
Ramp
Raised by about 0.1 mg a day every 2 weeks
  • The user said daily dosing avoided migraines and other side effects.
Sources (1)

Not testedFringe

Both mixed in one vial

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
20 mg retatrutide + 20 mg tirzepatide mixed in 3 mL; 25 units every 3 days
How often
Every 3 days
Route
Injection under the skin
Mixing
20 mg + 20 mg in 3 mL bacteriostatic water
  • Calculated 40 mg in 3 mL = 13.3 mg/mL, so 25 units (0.25 mL) = 3.3 mg in total, about 1.7 mg of each. The user called this ‘about 4mg’, which does not match the arithmetic.
Sources (1)

Where the numbers come from

User-built for stalls and transitions. No study has tested the two together.

Cautions

Research notes

Retatrutide is investigational and bought as research vials. Tirzepatide may be branded (Zepbound, Mounjaro), compounded or a research vial; the posts rarely say which. One user’s own dose arithmetic for a mixed vial was wrong (see protocol notes).

GLP-1 drug + MOTS-c (retatrutide or tirzepatide with MOTS-c)

Made ofRetatrutideTirzepatideMOTS-c

Some users add MOTS-c (from 1–2 mg a day to 5 mg every few days) to weekly retatrutide or tirzepatide for energy or extra fat loss. A widely discussed 2025 thread warned of very low night-time blood sugar on the combination, and others described vomiting and crashes.

Not testedSometimes seen

MOTS-c added to a weekly GLP-1 drug

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
MOTS-c 1–2 mg a day (or on weekdays), or 5 mg every 4 days, alongside retatrutide 1.5–8 mg a week
How often
MOTS-c daily, on weekdays, or every few days; the GLP-1 drug weekly
Route
Injection under the skin
Ramp
Users in the thread suggested starting MOTS-c at about 1 mg
Sources (4)

Where the numbers come from

User-built. MOTS-c is sold as an ‘exercise mimetic’ for energy and fat loss. There are no human trials of the combination.

Cautions

Research notes

Doses are unanchored; one poster ran 12 mg retatrutide + 15 mg tirzepatide + 5 mg MOTS-c daily, while others call 2 mg a day of MOTS-c high. The low-blood-sugar reports are self-reports, but one used a glucose monitor.

Sermorelin + ipamorelin

Made ofSermorelinIpamorelin

Sermorelin and ipamorelin are sold together as a 1:1 mixed vial, including by clinics, and taken nightly. Reported amounts run from about 170–200 mcg to 500 mcg a night.

More about this

Forum users mostly prefer CJC-1295 with ipamorelin instead.

Not testedSometimes seen

Nightly 1:1 mixed vial

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
About 167–200 mcg a night reported by users; one clinic prescribed 500 mcg a night from a 15 mg vial
How often
Once nightly
Route
Injection under the skin
Timing
At bedtime
How long
Months at a time; one user ran 4.5 months on
Cycle
Then 1.5 months off (one user)
  • Calculated 500 mcg a night uses up a 15 mg vial in 30 days, which the user suspected was the point of the prescription.
  • The 167 mcg figure is that user’s sermorelin dose (one 5 mg vial a month); he said he had used both sermorelin alone and a 1:1 sermorelin/ipamorelin mix.
Sources (4)

Where the numbers come from

Sermorelin was a prescription drug (Geref) and stayed in compounding pharmacies after it was discontinued. Anti-aging clinics paired it with ipamorelin on the same logic as CJC-1295/ipamorelin: a growth-hormone-releasing hormone mimic plus a ghrelin mimic.

Cautions

Research notes

Few dose reports were found; most forum threads compare sermorelin/ipamorelin with CJC-1295/ipamorelin rather than giving doses. The Reddit posts do not say whether their mcg figures are for the whole blend or for each peptide.

GLP-1 drug + growth-hormone-releasing peptides (CJC-1295/ipamorelin, often with BPC-157/TB4) to protect muscle

Made ofSemaglutideTirzepatideCJC-1295 (no DAC)IpamorelinBPC-157Thymosin Beta-4

Some clinics and users add CJC-1295/ipamorelin (and sometimes BPC-157/TB4) to a GLP-1 drug, hoping to limit muscle loss and low energy during weight loss. The peptide doses are the usual ones: CJC/ipamorelin 5 nights a week before sleep, BPC-157 daily and TB4 twice a week while loading.

Not testedSometimes seen

Clinic add-on during GLP-1 therapy

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Amounts per injection are not given on the page. The clinic describes CJC-1295/ipamorelin injected together at night, BPC-157 daily or twice daily, and TB4 twice a week while loading, then weekly.
How often
CJC/ipamorelin 5 nights a week; BPC-157 daily; TB4 twice weekly, then weekly
Route
Injection under the skin
Timing
CJC/ipamorelin before sleep
How long
CJC/ipamorelin 3 months on
Cycle
CJC/ipamorelin 1 month off; BPC-157 4–8 weeks on, 4 off
  • The clinic pairs this with at least 0.7–1.0 g of protein per pound of body weight and resistance training 2–3 times a week.
Sources (2)

Not testedSometimes seen

User stack: weekly tirzepatide + CJC/ipamorelin blend + BPC-157/TB4 blend

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
Tirzepatide 5 mg a week + 300 mcg of a 5 mg/5 mg CJC-1295/ipamorelin blend 5 days a week + 1,000 mcg of a BPC-157/TB4 blend daily
How often
Tirzepatide weekly; CJC/ipamorelin 5 days on, 2 off; BPC/TB4 daily
Route
Injection under the skin
  • Calculated 300 mcg of a 1:1 blend is 150 mcg each of CJC-1295 and ipamorelin; 1,000 mcg of a 1:1 BPC/TB4 blend is 500 mcg of each.
Sources (2)

Where the numbers come from

Clinic marketing around the finding that part of the weight lost on GLP-1 drugs is lean mass. The peptide parts reuse the standard CJC/ipamorelin and Wolverine protocols. No study has tested these peptides for muscle protection on GLP-1 drugs.

Cautions

Research notes

The clinic page does not give amounts per injection. Tesamorelin with a GLP-1 drug is also discussed on Reddit (for example ‘microdosing tirz, tesa/ipa’), but no dose reports were found for that pairing.

Sprays & serums: how people make their own, and the math